Home > Focus Areas > Multiple Myeloma Connect > Post
4yr
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33980053/
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the managemen ...
-
Mark Fesler4yrValuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
-
Multiple Myeloma Connect4yrPlease share your thoughts concerning overdose on oral chemotherapy.
-
Naveed Saleh, MD, MS – Skipta Team4yrPlease feel free to share your concerns about and professional experiences with overdose on oral chemotherapy.